143 related articles for article (PubMed ID: 38685034)
1. Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first.
Storwick JA; Tam H; Rosenbaum DG; Houghton K
Pediatr Rheumatol Online J; 2024 Apr; 22(1):49. PubMed ID: 38685034
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
[TBL] [Abstract][Full Text] [Related]
3. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
[TBL] [Abstract][Full Text] [Related]
4. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
7. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
10. A case of checkpoint inhibitor-induced celiac disease.
Alsaadi D; Shah NJ; Charabaty A; Atkins MB
J Immunother Cancer; 2019 Aug; 7(1):203. PubMed ID: 31383006
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
13. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
14. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
McQuade JL; Hammers H; Furberg H; Engert A; André T; Blumenschein G; Tannir N; Baron A; Larkin J; El-Khoueiry A; Carbone DP; Thomas JM; Hennicken D; Coffey M; Motzer RJ
JAMA Oncol; 2023 Jan; 9(1):102-111. PubMed ID: 36480191
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
16. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
17. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
18. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
